Upload
nguyenhanh
View
216
Download
0
Embed Size (px)
Citation preview
Claudio Borghi Dipartimento di Scienze Mediche e Chirurgiche Università di Bologna
Il rischio cardiovascolare
Age-adjusted death rates for diseases of the heart, cerebrovascular disease, and chronic lower respiratory disease by year.
Lackland D et Al., Stroke 2013;45:315-353
USA- 1900 to 2010
Complessità del rapporto NAFLD/NASH e malattie CV
NAFLD, NASH
Tipo di studio (Retr,Prosp,CS,Pop)
Smple size
Modalità valutazione epatopatia
(US,Biops,Lab.Index)
Outcome (MCV, Mort-CV, CHD, LVH, IMT..)
MS si/no, DM si/no
Principal studies of the association between NAFLD and the incidence of major CV events
Luo J et Al., Eur J Gastroenterology & Hepatology 2015, 27:193–199
Fatty Liver Index and risk of CHD
Gastaldelli A et al, Hepatology. 2009 49(5):1537-442008
Arch Turk Soc Cardiol 2008;36(6):376-381
Distribution of the percentage of patients having coronary stenosis of greater than 70% on a 4-point vessel scoring
Risk of CVD, CHD and CV target organ damage in patients with/without NAFLD/NASH (US,Histology,Liver enzyme)
Event Type of studies Evidence
CV mortality Retrospective Increased risk Prospective Increased risk
CHD/CVD Population-based Increased risk
LV structure Retrospective (1 Pr.) Increased LVH/AF Carotid IMT Cross-sectional Increased IMT/ATS
Fargion S et Al., World J Gastroenterol 2014 ; 20(37): 13306-13324 Ballestri S et Al., World J Gastroenterol 2014;20(7): 1724-1745
Increased arterial stiffness in nonalcoholic fatty liver disease: the Cardio-GOOSE study. Salvi, Paolo; Ruffini, Raffaele; Agnoletti, Davide; Magnani, Elena; Pagliarani, Gabriele; Comandini,
Giulia; Pratico, Antonino; Borghi, Claudio; Benetos, Athanase; Pazzi, Paolo
Journal of Hypertension. 28(8):1699-1707, August 2010.
Logistic regression analyses of factors associated with
incident CVD events among DM2 patients
Multivariate model adjusted for age, sex, smoking, diabetes duration, Hb A1C, LDL-C, GGT, use of medications (i.e., hypoglycemic, antihypertensive, lipid-lowering, or antiplatelet drugs), presence of MS
Targher G et al. Diabetes 54:3541–3546, 2005
……..
Quali meccanismi sono implicati nei rapporti tra NAFLD/NASH e rischio CV ?
NAFLD e rischio CV: possibili meccanismi
• Effetti primitivi della epatopatia
Forest plot of meta-analysis of fully adjusted study results of the association of GGT with incident CHD or stroke
Fraser A et al. Arterioscler. Thromb. Vasc. Biol. 2007;27;2729-2735
NAFLD e rischio CV: possibili meccanismi
• Effetti primitivi della epatopatia
• Effetti della sindrome metabolica associata
Population-based observational study in 1209 men without DM in the Kuopio Ischaemic Heart Disease Risk Factor Study
Lakka H-M, et al. JAMA. 2002;288:2709-2716.
Coronary Heart Disease Morality
Cardiovascular Disease Morality
All-Cause Mortality
Cum
ulat
ive
Haz
ard
(%)
20
15
10
5
0 0 2 4 6 8 10 12 0 2 4 6 8 10 12 0 2 4 6 8 10 12
Follow-up (y)
RR (95% CI): 3.55 (1.96–6.43) RR (95% CI): 2.43 (1.64–3.61) RR (95% CI): 3.77 (1.74–8.17)
Metabolic syndrome present Metabolic syndrome absent
Adverse Prognostic Implications of Metabolic Syndrome
The prevalence of subjects with or without the MS among 1874 men and 514 women with NFALD
Hamaguchi H et Al., World J Gastroenterol 2012; 18(13): 1508-1516
Increased arterial stiffness in nonalcoholic fatty liver disease: the Cardio-GOOSE study. Salvi, Paolo; Ruffini, Raffaele; Agnoletti, Davide; Magnani, Elena; Pagliarani, Gabriele; Comandini,
Giulia; Pratico, Antonino; Borghi, Claudio; Benetos, Athanase; Pazzi, Paolo
Journal of Hypertension. 28(8):1699-1707, August 2010.
PWV, IMT and carotid plaques in patients with NAFLD and/or MS
NAFLD e rischio CV: possibili meccanismi
• Effetti primitivi della epatopatia
• Effetti della sindrome metabolica associata
• Effetti delle resistenza insulinica/iperinsulinemia
Fatty liver index and insulin resistance
*p<0.001 after correcting for age, center, gender, alcohol intake and physical activity
* *
Peripheral insulin sensitivity
* *
Adiponectin
0
2
4
6
8
10
12
FLI<20 FLI<60 FLI>60
Glu
cose
dis
posa
l (m
mol
/min
Kg f
fm) *
*
Hepatic Insulin resistance
0
200
400
600
800
FLI<20 FLI<60 FLI>60
Fast
ing
EG
PxI
nsul
in
(mm
ol/m
in K
g ffm
x p
mol
/l)
0
10
20
30
40
50
60
70
FLI<20 FLI<60 FLI>60
Fasting Insulin
* *
Insu
lin
conc
entra
tion
(pm
ol/l)
0
10
20
30
40
50
60
FLI<20 FLI<60 FLI>60
ng/m
l
Gastaldelli A et al, Hepatology. 2009 49(5):1537-44
Q1 to Q5=quintiles of area under the curve (AUC) insulin (Q1=lowest quintile; Q5=highest quintile).
Proportion without major CHD event
Years 0
0 5
0.75
0.80
0.85
0.90
0.95
1.00
10 15 20 25
Log rank: Overall P=.001 Q5 vs Q1 P<.001
Q1
Q2
Q3 Q4
Q5
Kaplan-Meier Survival Curve
Pyörälä M et al. Circulation 1998;98:398–404.
Risk of Major CHD Event Associated With High Insulin Levels in Nondiabetic Men
NAFLD, Insulin resistance and CV diseases: Possible Links
NAFLD
Insulin Resistance
Compensatory Hyperinsulinemia
Heightened Sympathetic Neural Activity
Functional and structural
vascular involvement
Glucose Uptake
Exaggerated Salt and Water Retention
RAS activation
.
NAFLD e rischio CV: possibili meccanismi
• Effetti primitivi della epatopatia
• Effetti della sindrome metabolica associata
• Effetti delle resistenza insulinica/iperinsulinemia
• Effetti della interazione Ins-Res/RAAS (AT1R)
The boxes enclosed with dashed lines are overlapping effects of Insulin and Ang II
The solid enclosed box is an effect of insulin only
Clinically overlapping effects of Insulin and angiotensin II
Townsend RR. Current Hypertension Reports 2003, 5:110-116
Effects of insulin on AT1 receptor mRNA expression in rat aortic SMC
Nickenig G et al, Basic Res Cardiol 1998
Gross MC et al, basic res cardiol 2002
SURFACE AREA STAINING FOR AT1 RECEPTOR AND DEGREE OF ATHEROSCLEROSIS (stary grade) IN HUMAN CORONARY ARTERIES
Effect of AT1 angiotensin receptor antagonist on luminal surface area of atherosclerotic lesion in the aorta of Apo-E KO mice.
Kato M et Al., J Cardiovasc Pharmacol 2006;47:764-769
Hyperinsulinemia
AT1 receptor expression
Functional vascular damage
ATS & CV disease
Working hypothesis on the possible interactions between NAFLD, RAS activation, angio-II and CV diseases
Insulin resistance
NAFLD
Hystological sections of right atrial free wall from a sham dog, a fifth week rapid pacing dog, and a fifth week rapid pacing dog with candesartan
Kumagai K et Al., JACC 2003
Prevalence of excessive fibrosis in atenolol- and losartan-treated patients at baseline and after 36 week treatment
Ciulla MM. Hypertension. 2004; 110:552-557.
Therapy
57% 69%
Atenolol Losartan
61% 48%
Baseline
Evidenze e prospettive • I pazienti con NAFLD presentano un rischio elevato di malattie CV.
• Tale elevata probabilità è legata alla presenza di un eccesso di fattori di rischio CV associati alla presenza di di insulino-resistenza .
• La presenza di NAFLD è associata alla presenza di una condizione pro-aterogena e caratterizzata da resistenza insulinica (70%), SM e profilo pro-infiammatorio.
• Il particolare profilo di rischio CV della NAFLD potrebbe conseguire alla iperattività del sistema nervoso simpatico e/o del sistema RAS che potrebbero spiegare lo sviluppo di ATS, l’aumento del rischio CV e anche contribuire alla progressione del danno epatico (?) ed influenzare le scelte terapeutiche.